Indoleamine 2,3-dioxygenase (IDO) Inhibitor Development Service for Cancer Immunotherapy

Background of Indoleamine 2,3-dioxygenase (IDO) Inhibitor Development

Indoleamine 2,3-dioxygenase (IDO) is an enzyme that plays a key role in tryptophan metabolism. It has three isoforms - IDO1, IDO2, and TDO. In cancer, the inflammation induced by tumor growth can lead to the overexpression of IDO in tumor cells and surrounding tissue. This may result in tryptophan depletion, hindering immune cell function and dampening the local immunological response in the tumor microenvironment. As a result, inhibiting IDO expression is being explored as a potential strategy for cancer immunotherapy.

Fig.1 Modulation of IDO1 overexpression and immune suppression in the tumor microenvironment.¹

Our Indoleamine 2,3-dioxygenase (IDO) Inhibitor Development Service for Cancer Immunotherapy: Short-turnaround! High-quality!

Incorporating medicinal chemistry, structural biology, and others, Creative Biolabs delivers a cost-effective indoleamine 2,3-dioxygenase (IDO) inhibitor development service for global customers to improve cancer immunotherapy. We provide a comparable complete targets library to help customers select the desirable targets for IDO inhibitor development. Several cutting-edge technologies such as high-throughput screening and smarter computer-aided design, enable our service compatible with different conditions. Based on it, we can develop variable inhibitor formats for customers' multiple uses.

Furthermore, we also provide tests to identify the candidate inhibitors to ensure their superior efficiency, selectivity, specificity, and other aspects. In addition, we have the capacity to construct research models for the toxicological assessment of candidate IDO inhibitors. Collectively, we provide a one-stop customized comprehensive service to assist global customers in developing effective IDO inhibitors and applying them to clinical trials.

Workflow for Indoleamine 2,3-dioxygenase (IDO) Inhibitor Development Service

Fig.2 Workflow.

• Target Screening: Screening candidate compounds by high-throughput screening technology and computer-aided drug design.
• Molecular Design: Based on the screening results, we synthesize compounds and examine them for activity.
• Molecular Optimize: We improve the potency, selectivity, and specificity of candidate inhibitors through continuous optimization and improvement.
• Pharmacokinetics Evaluation: We evaluate the absorption, distribution, metabolism, and excretion properties of candidate inhibitors in vivo.
• Toxicology Evaluation: We evaluate the safety and potential side effects of candidate inhibitors.
• Clinical Prediction: We make an intelligent prediction of clinical outcomes based on candidate inhibitors' preclinical data.

Indoleamine 2,3-dioxygenase (IDO) Inhibitor Types at Creative Biolabs

• Tryptophan analogs.
• Small molecule inhibitors based on structure design.
• Novel compounds based on high-throughput screening.
• Several tyrosine kinase inhibitors.

Frequently Asked Question

Q1: What is the mechanism of action of IDO inhibitors?

A1: IDO is an enzyme that can hinder the immune system's ability to combat tumors by breaking down tryptophan, an essential amino acid for T cells. This degradation leads to the inhibition of T-cell function, allowing the tumor to evade detection. However, IDO inhibitors can block this process, restoring T cell activity and potentially enhancing the body's ability to fight against cancer cells.

For more details about our indoleamine 2,3-dioxygenase (IDO) inhibitor development service for cancer immunotherapy, please feel free to get in touch with us.

Reference

1. Song, Xiaotian, et al. "Indoleamine 2, 3-dioxygenase 1: a promising therapeutic target in malignant tumor." Frontiers in Immunology 12 (2021): 800630.

For Research Use Only | Not For Clinical Use